18F-氟胆碱PET/CT与99mTc-MIBI或99mTc-四氟膦SPECT/CT评估原发性甲状旁腺功能亢进症的前瞻性双中心100例研究
前瞻性双中心研究纳入100例生化证实的原发性甲状旁腺功能亢进症患者,比较18F-氟胆碱PET/CT与99mTc-MIBI或99mTc-四氟膦SPECT/CT术前检出甲状旁腺腺瘤的准确性,并评估半定量参数鉴别增生与腺瘤的价值。最终分析82例,18F-氟胆碱PET/CT基于患者的检出率为93%(76/82),99mTc-MIBI/四氟膦SPECT/CT为61%(50/82)。作者认为18F-氟胆碱PET/CT前景良好,明显优于99mTc-MIBI/四氟膦SPECT/CT,但还需进一步评估。
要点
- 基于患者分析,18F-氟胆碱PET/CT检出率93%(76/82),99mTc-MIBI/四氟膦SPECT/CT为61%(50/82)。
- 基于病灶分析,18F-氟胆碱PET/CT灵敏度93.7%、特异度96.0%、准确率95.3%。
- 腺瘤SUVmax 6.80±3.78高于增生腺体4.53±0.40,但差异无统计学意义(p=0.236)。
核心结论
- 作者认为18F-氟胆碱PET/CT作为一种功能影像方法前景良好,明显优于99mTc-MIBI/四氟膦SPECT/CT,尤其在小甲状旁腺腺瘤的检出与定位方面。
- 作者指出甲状旁腺腺瘤的SUVmax高于增生腺体,但该模态还需进一步评估。
研究设计与样本
- 前瞻性双中心研究,连续纳入100例有生化证据的原发性甲状旁腺功能亢进症患者,均行18F-氟胆碱PET/CT与99mTc-MIBI或99mTc-四氟膦SPECT/CT。
- 至少一种影像出现对应甲状旁腺或异位甲状旁腺组织的异常浓聚灶即视为阳性。
- 76例至少一种影像阳性者在6个月内行手术探查,以组织病理学及3-6个月临床和实验室结果为标准真相;24例未手术(18例影像阳性但拒绝手术或认为手术有风险,6例影像阴性)。
- 最终分析82例(76例手术、6例未手术)符合标准真相标准者的数据。
主要发现
- 全部患者均有原发性甲状旁腺功能亢进症生化证据,平均血清钙2.78±0.34 mmol/l,甲状旁腺激素(PTH)196.5±236.4 pg/ml。
- 基于患者分析,18F-氟胆碱PET/CT检出率93%(76/82),99mTc-MIBI/四氟膦SPECT/CT为61%(50/82)。
- 基于病灶分析,18F-氟胆碱PET/CT灵敏度93.7%、特异度96.0%、阳性预测值90.2%、阴性预测值97.4%、总准确率95.3%;99mTc-MIBI/四氟膦SPECT/CT分别为60.8%、98.5%、94.1%、86.3%、87.7%。
- 半定量分析中,18F-氟胆碱PET阳性的腺瘤病灶SUVmax为6.80±3.78,高于增生腺体的4.53±0.40,但差异无统计学意义(p=0.236)。
- 腺瘤平均大小(最大径)15.9±7.6 mm(中位15 mm,范围1-40 mm),平均重量1.71±1.86 g(中位1 g,范围0.25-9 g);99mTc-MIBI/四氟膦SPECT/CT阴性组与阳性组腺瘤平均大小分别为13.4±7.6 mm与16.9±7.4 mm,差异有统计学意义(p=0.042)。
关键数值与推荐
- 基于患者检出率:18F-氟胆碱PET/CT 93%(76/82)vs 99mTc-MIBI/四氟膦SPECT/CT 61%(50/82)。
- 基于病灶灵敏度:18F-氟胆碱PET/CT 93.7% vs 99mTc-MIBI/四氟膦SPECT/CT 60.8%。
- 基于病灶特异度:18F-氟胆碱PET/CT 96.0% vs 99mTc-MIBI/四氟膦SPECT/CT 98.5%。
- 基于病灶总准确率:18F-氟胆碱PET/CT 95.3% vs 99mTc-MIBI/四氟膦SPECT/CT 87.7%。
- 腺瘤与增生SUVmax:6.80±3.78 vs 4.53±0.40,p=0.236。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 作者在结论中指出该模态还需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In this prospective study we compared the accuracy of 18F-fluorocholine PET/CT with that of 99mTc-MIBI or99mTc-tetrofosmin SPECT/CT in the preoperative detection of parathyroid adenoma in patients with primary hyperparathyroidism. We also assessed the value of semiquantitative parameters in differentiating between parathyroid hyperplasia and adenoma. METHODS: Both 18F-fluorocholine PET/CT and 99mTc-MIBI/tetrofosmin SPECT/CT were performed in 100 consecutive patients with biochemical evidence of primary hyperparathyroidism. At least one abnormal focus on either 18F-fluorocholine or 99mTc-MIBI/tetrofosmin corresponding to a parathyroid gland or ectopic parathyroid tissue was considered as a positive finding. In 76 patients with positive findings on at least one imaging modality, surgical exploration was performed within 6 months, and the results were related to histopathological findings and clinical and laboratory findings at 3-6 months as the standard of truth. In 24 patients, no surgery was performed: in 18 patients with positive imaging findings surgery was refused or considered risky, and in 6 patients imaging was negative. Therefore, data from 82 patients (76 undergoing surgery, 6 without surgery) in whom the standard of truth criteria were met, were used in the final analysis. RESULTS: All patients showed biochemical evidence of primary hyperparathyroidism with a mean serum calcium level of 2.78 ± 0.34 mmol/l and parathormone (PTH) level of 196.5 ± 236.4 pg/ml. The study results in 76 patients with verified histopathology and 3 patients with negative imaging findings were analysed. Three of six patients with negative imaging showed normalized serum PTH and calcium levels on laboratory follow-up at 3 and 6 months, and the results were considered true negative. In a patient-based analysis, the detection rate with 18F-fluorocholine PET/CT was 93% (76/82), but was only 61% (50/82) with 99mTc-MIBI/tetrofosmin SPECT/CT. In a lesion-based analysis, the sensitivity, specificity, positive predictive value, negative predictive value and overall accuracy of 18F-fluorocholine PET/CT in the detection of parathyroid adenoma were 93.7%, 96.0%, 90.2%, 97.4% and 95.3%, respectively, and of 99mTc-MIBI/tetrofosmin SPECT/CT were 60.8%, 98.5%, 94.1%, 86.3% and 87.7%, respectively. Although 18F-fluorocholine PET-positive adenomatous lesions showed higher SUVmax values than the hyperplastic glands (6.80 ± 3.78 vs. 4.53 ± 0.40) in the semiquantitative analysis, the difference was not significant (p = 0.236). The mean size (measured as the length of the greatest dimension) and weight of adenomas were 15.9 ± 7.6 mm (median 15 mm, range 1-40 mm) and 1.71 ± 1.86 g (median 1 g, range: 0.25-9 g), respectively. Among the analysed parameters including serum calcium and PTH and the size and weight of parathyroid adenomas, size was significantly different between patients with negative 99mTc-MIBI/tetrofosmin SPECT/CT and those with positive 99mTc-MIBI/tetrofosmin SPECT/CT (mean size 13.4 ± 7.6 mm vs. 16.9 ± 7.4 mm, respectively; p = 0.042). CONCLUSION: In this prospective study, 18F-fluorocholine PET/CT showed promise as a functional imaging modality, being clearly superior to 99mTc-MIBI/tetrofosmin SPECT/CT, especially in the detection and localization of small parathyroid adenomas in patients with primary hyperparathyroidism. SUVmax was higher in parathyroid adenomas than in hyperplasia. However, further evaluation of this modality is needed.
引用
- Beheshti M, Hehenwarter L, Paymani Z, et al. 18F-Fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with 99mTc-MIBI or 99mTc-tetrofosmin SPECT/CT: a prospective dual-centre study in 100 patients. Eur J Nucl Med Mol Imaging. 2018. PMID: 29516131. doi:10.1007/s00259-018-3980-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。